Antiphospholipid Antibody Syndrome (APLA/APS): Risk Factors and Pathophysiology

Definition

• Recurrent venous and/or arterial thrombosis
• Obstetric morbidity (recurrent pregnancy loss, fetal death, premature birth)
• Persistently positive antiphospholipid antibodies (aPL) on two or more occasions at least 12 weeks apart

1. Lupus anticoagulant (LA)
2. Anticardiolipin antibodies (aCL) - IgG/IgM, moderate-to-high titer
3. Anti-β2-glycoprotein I (anti-β2GPI) - IgG/IgM, moderate-to-high titer

Risk Factors

1. Autoimmune Disease (Strongest Association)

• Systemic Lupus Erythematosus (SLE) is the most important predisposing condition. aPL antibodies are found in 25-75% of SLE patients; 34% are positive for lupus anticoagulant and 44% for anticardiolipin antibodies across published series. Most SLE patients with aPL never develop clinical APS - a "second hit" is required. - Brenner and Rector's The Kidney
• Other connective tissue diseases (rheumatoid arthritis, Sjögren's syndrome, systemic sclerosis) also confer risk.

2. Primary vs. Secondary APS

• Primary APS (30-55%): No associated autoimmune disease - aPL arise in isolation.
• Secondary APS: Occurs in the setting of SLE or other autoimmune conditions. - Brenner and Rector's The Kidney

3. Genetic/Immunogenetic Predisposition

• Among SLE patients, HLA-DRB1 loci are associated with susceptibility to developing aPL antibodies.
• Rare germline variants in complement regulatory genes (e.g., CFH, CFI) are found in ~60% of patients with catastrophic APS versus ~22% in thrombotic APS - highlighting a genetic complement dysregulation component. - Medscape/eMedicine; web search 2025
• Family members of APS patients have elevated risk of autoimmune disease and aPL positivity.

4. Infectious Triggers

• Infections (HIV, hepatitis C virus [HCV], syphilis, malaria, bacterial infections) can transiently induce aPL antibodies - but these infection-related antibodies are usually NOT associated with clinical APS (they lack β2GPI cofactor dependence).
• aPL are found in up to 2% of normal individuals and more frequently with infections. - Brenner and Rector's The Kidney

5. Drug-induced aPL

• Certain drugs (chlorpromazine, procainamide, phenytoin, hydralazine, quinidine) can induce anticardiolipin antibodies - again typically non-pathogenic, without clinical APS manifestations.

6. Hormonal / Physiologic "Second Hits"

• Pregnancy (creates a hypercoagulable state: increased thrombin generation, impaired fibrinolysis via placental PAI-2, platelet activation)
• Oral contraceptive use and hormone replacement therapy
• Nephrotic syndrome (urinary loss of anticoagulant proteins S, C, antithrombin)
• Hyperlipidemia
• Immobilization, surgery, or trauma
• Intercurrent infection or inflammation - Brenner and Rector's The Kidney; Goldman-Cecil Medicine

7. Demographic Factors

• Female sex predominates (F:M ratio ~3-4:1), consistent with autoimmune disease predilection.
• Peak incidence in reproductive-age women.
• Non-white ethnicity may confer higher risk for worse outcomes in the context of SLE-associated APS.

Pathophysiology

Step 1: The Autoantigen - β2-Glycoprotein I (β2GPI)

• Domain V (DV): Positively charged; binds to anionic phospholipids on activated endothelium, platelets, and apoptotic cells. This induces a conformational change from a closed circular to an open "J-shaped/fishhook" structure.
• Domain I (DI) epitope (Arg39-Arg43): Once β2GPI opens, this epitope is exposed and becomes the principal target of pathogenic autoantibodies. Anti-DI antibodies are specifically thrombogenic.
• Antibodies binding DI are highly specific for clinical APS; antibodies to other domains are less pathogenic.

Step 2: Endothelial Cell Activation

• Upregulation of adhesion molecules: ICAM-1, VCAM-1, E-selectin are expressed on endothelium, promoting leukocyte-endothelial interactions and the inflammatory state.
• Tissue factor (TF) generation: Both monocytes and vascular endothelium generate TF upon aPL stimulation, directly initiating the extrinsic coagulation cascade.
• eNOS inhibition: aPL binding to DI of β2GPI impairs endothelial nitric oxide synthase (eNOS) phosphorylation, reducing NO synthesis. NO normally inhibits platelet aggregation and promotes vasodilation - its loss creates a prothrombotic, vasoconstrictive environment.
• MAPK and NF-κB pathway activation: aPL binding increases signaling through these pathways, amplifying pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6). - Braunwald's Heart Disease; Metabolites 2025

Step 3: Platelet Activation

• aPL (especially anti-β2GPI) bind to β2GPI on the platelet surface, directly activating platelets.
• Activated platelets synthesize and release thromboxane A2 (TXA2), a potent platelet aggregator and vasoconstrictor - amplifying the procoagulant state.
• Platelets also expose anionic phospholipids on their surface, providing the "phospholipid scaffold" upon which coagulation complexes (tenase, prothrombinase) assemble more efficiently.
• The result is thrombocytopenia (platelet consumption in microthrombi) combined with paradoxical thrombosis. - Braunwald's Heart Disease

Step 4: Coagulation Cascade Interference

• The net effect of coagulation protein interference is impaired fibrinolysis alongside enhanced clot formation.
• aPL binding to prothrombin can also inhibit thrombin inactivation, prolonging the procoagulant state.
• Lupus anticoagulant - paradoxically - prolongs the aPTT in vitro (competing for phospholipid in the assay) but causes thrombosis in vivo. - Brenner and Rector's The Kidney; Robbins Basic Pathology

Step 5: Complement Activation

• aPL (especially anti-β2GPI) activate the classical complement pathway, generating C5a and the membrane attack complex (MAC/C5b-9).
• C5a recruits and activates neutrophils and promotes endothelial injury.
• In pregnancy loss, complement activation at the placenta is a primary pathogenic mechanism - animal models show that inhibiting complement prevents fetal loss even in the presence of aPL.
• NETs (neutrophil extracellular traps): aPL-activated neutrophils undergo NETosis, releasing DNA-protein complexes that:
  • Provide a scaffold for thrombus formation
  • Act as a source of autoantigens (amplifying aPL production)
  • Activate the complement cascade further
• Anti-NET antibodies in primary APS impair NET clearance, sustaining complement activation in a pathogenic positive-feedback loop.
• Catastrophic APS is strongly associated with complement regulatory gene variants (CFH, CFI), underscoring complement dysregulation as a driver of the most severe disease. - Braunwald's Heart Disease; Medscape 2025; web search (PMC 2025)

Step 6: The "Two-Hit Model" for Thrombosis

aPL positivity (Hit 1)
        +
Second trigger (Hit 2): infection, pregnancy, OCP, complement activation, surgery
        ↓
Overt clinical thrombosis / obstetric event

• Most aPL-positive individuals never develop thrombosis
• Thrombotic events are often precipitated by identifiable triggers
• Infection-induced aPL (without β2GPI dependence) rarely cause APS

Obstetric Pathophysiology

1. Placental thrombosis - thrombosis of spiral arteries, intervillous space, and decidual vessels causing placental insufficiency and fetal death.
2. Complement-mediated placental injury - aPL-induced C3a and C5a activation at the trophoblast-decidua interface causes:
   • Direct trophoblast apoptosis and injury
   • Reduced trophoblast invasiveness
   • Impaired placentation and spiral artery remodeling
3. Direct trophoblast dysfunction - aPL inhibit trophoblast differentiation and invasive capacity independently of thrombosis.
4. Annexin V disruption - displaces the anticoagulant annexin V shield on trophoblast surfaces, promoting local clotting. - Creasy & Resnik's Maternal-Fetal Medicine

Histopathology

Summary Diagram of Pathophysiology

Susceptible host (HLA-DRB1, complement gene variants)
           ↓
Exposure: infection, drugs, autoimmune trigger
           ↓
aPL production (anti-β2GPI, LA, aCL)
           ↓
β2GPI binds anionic phospholipids → opens to "J" shape
           ↓
aPL binds Domain I of β2GPI on endothelium / platelets / monocytes
           ↓
┌──────────────────────────────────────┐
│  Endothelial activation:             │
│  ↑TF, ↑adhesion molecules, ↓eNOS    │
│                                      │
│  Platelet activation:                │
│  ↑TXA2, ↑phospholipid scaffold       │
│                                      │
│  Coagulation protein disruption:     │
│  ↓Protein C/S, ↓Annexin V, ↓tPA     │
│                                      │
│  Complement activation:              │
│  C5a → neutrophil activation → NETs  │
└──────────────────────────────────────┘
           ↓
    Second hit (pregnancy, infection, OCP...)
           ↓
     THROMBOSIS / PREGNANCY LOSS

Recent Evidence Update (2024-2025)

Note: These recent reviews emphasize that complement inhibition (e.g., eculizumab) and NET-targeting strategies are emerging as therapeutic options, particularly in catastrophic APS - suggesting these pathways are not only mechanistically central but also clinically actionable.